AQR Capital Management LLC Boosts Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

AQR Capital Management LLC raised its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 10.6% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 90,166 shares of the specialty pharmaceutical company’s stock after buying an additional 8,672 shares during the period. AQR Capital Management LLC owned about 0.18% of Supernus Pharmaceuticals worth $2,822,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in SUPN. Ameritas Investment Partners Inc. purchased a new position in Supernus Pharmaceuticals during the first quarter valued at approximately $127,000. Fortaleza Asset Management Inc. purchased a new position in Supernus Pharmaceuticals during the first quarter valued at approximately $160,000. State of Alaska Department of Revenue boosted its position in Supernus Pharmaceuticals by 3.2% in the first quarter. State of Alaska Department of Revenue now owns 5,530 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 170 shares during the period. OppenheimerFunds Inc. purchased a new position in Supernus Pharmaceuticals during the first quarter valued at approximately $205,000. Finally, First Citizens Bank & Trust Co. purchased a new position in Supernus Pharmaceuticals during the first quarter valued at approximately $208,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Supernus Pharmaceuticals, Inc. (SUPN) traded down 0.69% during mid-day trading on Friday, reaching $43.20. 626,131 shares of the company traded hands. The stock has a market capitalization of $2.19 billion, a PE ratio of 21.80 and a beta of 1.31. Supernus Pharmaceuticals, Inc. has a 52-week low of $17.25 and a 52-week high of $46.45. The firm’s 50-day moving average is $42.56 and its 200 day moving average is $34.77.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.08. The company had revenue of $75.83 million for the quarter, compared to analysts’ expectations of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. On average, equities research analysts expect that Supernus Pharmaceuticals, Inc. will post $1.04 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.com-unik.info/2017/08/19/aqr-capital-management-llc-boosts-position-in-supernus-pharmaceuticals-inc-nasdaqsupn-updated-updated-updated.html.

Several research analysts have commented on SUPN shares. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price target for the company in a report on Thursday, July 13th. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 24th. Jefferies Group LLC set a $35.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, May 10th. Stifel Nicolaus restated a “buy” rating and set a $47.00 price objective (up previously from $36.00) on shares of Supernus Pharmaceuticals in a research report on Tuesday, July 18th. Finally, Piper Jaffray Companies downgraded shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $46.00 price objective for the company. in a research report on Monday, July 17th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $48.43.

In related news, VP Padmanabh P. Bhatt sold 2,500 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $35.90, for a total transaction of $89,750.00. Following the sale, the vice president now directly owns 37,500 shares in the company, valued at $1,346,250. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 10,000 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $39.86, for a total value of $398,600.00. Following the transaction, the vice president now directly owns 27,500 shares in the company, valued at $1,096,150. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,000 shares of company stock worth $1,130,524. Company insiders own 6.70% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

What are top analysts saying about Supernus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit